Pyoverdine-Dependent Virulence of Pseudomonas aeruginosa Isolates From Cystic Fibrosis Patients
Open Access
- 6 September 2019
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 10, 2048
Abstract
The development of therapies that modulate or prevent pathogen virulence may be a key strategy for circumventing antimicrobial resistance. Toward that end, we examined the production of pyoverdine, a key virulence determinant, in ∼70 Pseudomonas aeruginosa isolates from pediatric cystic fibrosis patients. Pyoverdine production was heterogeneous and showed a clear correlation with pathogenicity in Caenorhabditis elegans and an acute murine pneumonia model. Examination showed pyoverdine accumulation in host tissues, including extrapharyngeal tissues of C. elegans and lung tissues of mice, where accumulation correlated with host death. Many of the isolates tested were resistant to multiple antimicrobials, so we assayed the ability of pyoverdine inhibitors to mitigate virulence and rescue pyoverdine-mediated host pathology. Representatives from three different classes of pyoverdine inhibitors (gallium, fluoropyrimidines, and LK11) significantly improved survival. Our findings highlight the utility of targeting virulence factors in general, and pyoverdine in particular, as a promising method to control bacterial pathogenesis as the utility of antimicrobials continues to diminish.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases
- National Institute of General Medical Sciences
- Welch Foundation
This publication has 59 references indexed in Scilit:
- Ferrous Iron Is a Significant Component of Bioavailable Iron in Cystic Fibrosis AirwaysmBio, 2013
- Repurposing the antimycotic drug flucytosine for suppression ofPseudomonas aeruginosapathogenicityProceedings of the National Academy of Sciences, 2013
- Pseudomonas siderophores in the sputum of patients with cystic fibrosisBioMetals, 2011
- Management of refractory Pseudomonas aeruginosa infection in cystic fibrosisInfection and Drug Resistance, 2011
- In Vitro and Murine Efficacy and Toxicity Studies of Nebulized SCC1, a Methylated Caffeine-Silver(I) Complex, for Treatment of Pulmonary InfectionsAntimicrobial Agents and Chemotherapy, 2009
- The transition metal gallium disrupts Pseudomonas aeruginosa iron metabolism and has antimicrobial and antibiofilm activityJournal of Clinical Investigation, 2007
- Antibiotics as intermicrobial signaling agents instead of weaponsProceedings of the National Academy of Sciences, 2006
- Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patientsProceedings of the National Academy of Sciences, 2006
- Whole-Genome Sequence Variation among Multiple Isolates of Pseudomonas aeruginosaJournal of Bacteriology, 2003
- Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosisPediatric Pulmonology, 2002